This work was supported by Medical College of Georgia Intramural Scientist Training Program to N. S. Conflict of interest: The authors declare no financial or commercial conflict of interest. Detailed facts of importance to specialist readers are published as ”Supporting Information”. Such documents are peer-reviewed, but not copy-edited or typeset. They are made available as submitted by MLN8237 clinical trial the authors.

“
“The autoimmune reaction is recently suspected to play a role in the pathogenesis of chronic obstructive lung disease (COPD). As COPD is a systemic disease, the elements of an autoimmune response in circulatory system is of interest. It has been shown that regulatory T cells are important in the control of autoimmunity. There are some data on a role of adiponectin in the regulation of immune reactions. The objective of this study was to assess the elements of autoimmune reaction in the peripheral blood (PB) of patients with COPD. Twenty-eight patients with mild/moderate COPD and 20 healthy volunteers learn more were investigated. Flow cytometry method with mixtures of monoclonal antibodies anti: CD14/CD45, CD3/CD19, CD4/CD25/CTLA4 and CD8/CD25 were used. Concentration of adiponectin was measured using ELISA method. We observed significantly lower proportion of CD4+/CD25+ as well as CD4+/CD25+ high

cells in COPD patients than in healthy controls (15.3 versus 17.8% and 0.79 versus 1.54%, respectively, P < 0.05). The proportion of CTLA4+ cells in CD25+ cells and

the mean fluorescence of CTLA4 on CD4+ buy Rucaparib cells were higher in patients than in healthy controls (10.4 versus 4.7%, P < 0.05, 189% versus 149%, non significant, respectively). We found significantly elevated concentration of adiponectin in patients when compared to healthy subjects (15.4 versus 8.5 μl/ml, P < 0.05). We found that the adiponectin/BMI ratio correlated with the decrease of FEV1%. The results of this study support the possible role of CD4/CD25/CTLA4 cells and adiponectin in the systemic inflammation in COPD. Chronic obstructive pulmonary disease (COPD) is a progressive disorder, characterized by poorly reversible airway obstruction and persistent inflammation in the lung tissue [1]. This disease affects mainly the respiratory tract. However, many data confirmed relevant systemic disturbances in course of COPD [2, 3, 4]. Up to date, the following pathways in systemic inflammation in COPD have been described: cytotoxic effect of CD8+ cells, elevated concentration of inflammatory cytokines, increased apoptosis of inflammatory cells and impaired resolution of inflammation [2, 3, 5–9]. There is evidence that activated lymphocytes play a crucial role in the pathogenesis and in the adaptive immune response in COPD [6]. Microbial peptide antigens are well known to be active in development of adaptive immunity [8]. However, recently some autoantigens were postulated to play important role in pathogenesis of COPD [10–12].